IQVIA Holdings Inc. $IQV Shares Sold by Formuepleje A S

Formuepleje A S reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 19,920 shares of the medical research company’s stock after selling 3,345 shares during the quarter. Formuepleje A S’s holdings in IQVIA were worth $5,355,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Ascentis Independent Advisors acquired a new stake in IQVIA in the first quarter valued at $25,000. Financial Freedom LLC acquired a new position in IQVIA in the first quarter valued at $25,000. Compass Financial Management LLC bought a new stake in IQVIA during the second quarter valued at $27,000. Elevation Wealth Partners LLC boosted its position in IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 105 shares during the last quarter. Finally, Caitlin John LLC acquired a new stake in IQVIA during the 2nd quarter worth about $31,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Barclays lifted their price objective on IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Mizuho lifted their price target on shares of IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. UBS Group began coverage on IQVIA in a research report on Wednesday, September 30th. They set a “buy” rating and a $345.00 target price on the stock. Stifel Nicolaus raised their price target on shares of IQVIA from $276.00 to $303.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $276.00.

IQVIA Stock Performance

NYSE IQV traded up $7.58 during trading on Thursday, hitting $269.59. 345,078 shares of the company’s stock traded hands, compared to its average volume of 1,698,641. The business has a 50 day moving average of $259.41 and a 200-day moving average of $211.71. The stock has a market capitalization of $44.38 billion, a price-to-earnings ratio of 33.44, a PEG ratio of 2.26 and a beta of 1.17. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $277.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 15,581 shares of company stock worth $3,796,021. Company insiders own 1.70% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.